NCT00511316View on ClinicalTrials.gov

Trial of Montelukast in Eosinophilic Esophagitis

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

Montelukast/ Singulair

20 mg daily for six months

DRUG

Placebo

Placebo 20 mg daily for 6 months

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Mayo Clinic

OTHER

NCT00511316 - Trial of Montelukast in Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter